Mechanisms of murine dendritic cell antitumor dysfunction in aging |
| |
Authors: | Annabelle Grolleau-Julius Lisa Abernathy Erin Harning Raymond L Yung |
| |
Institution: | (1) Divisions of Geriatric Medicine and Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0940, USA;(2) GRECC, Veteran Affairs Ann Arbor Healthcare System, Ann Arbor, USA;(3) Room 3023 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA |
| |
Abstract: | Effective cancer immunotherapy depends on the body’s ability to generate tumor antigen-presenting cells and tumor-reactive
effector lymphocytes. As the most potent antigen presenting cells (APCs), dendritic cells (DCs) are capable of sensitizing
T cells to new and recall antigens. Clinical trials of antigen-pulsed autologous DCs have been conducted in patients with
a number of hematological and solid cancers, including malignant melanoma, lymphoma, myeloma, and non-small cell lung cancer.
These studies suggest that antigen-loaded DC vaccination is a potentially safe and effective cancer therapy. However, the
clinical results have been variable. Since the elderly are preferentially affected by diseases targeted by DC-directed immunotherapy,
it is quite striking that few studies to date have focused on the effect of aging on DC function, a key aspect of optimal
immunotherapy design in an aging population. In the present paper, we will discuss the consequences of aging on murine bone
marrow-derived DC function and their use in cancer immunotherapy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|